Compare Adaptive Biotechnologies Corp (ADPT) vs Barrick Gold Corp (B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Barrick Gold Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.03 (market cap $3.33B), while Barrick Gold Corp trades at $35.48 (market cap $61.76B). The key difference: Barrick Gold Corp is far larger — about 18.5× Adaptive Biotechnologies Corp's market cap, and Barrick Gold Corp pays a 1.9% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | B | |
|---|---|---|
Market Cap | $3.33B | $61.76B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $52.97 |
52-Week Low | $10.24 | $20.73 |
Enterprise Value | $3.19B | $59.35B |
Dividend Yield | — | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Barrick Mining (B) trades at $36.86, down 3.55% over 24 hours, with technical indicators signaling a bearish trend. The company demonstrates strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and consistent earnings beats in recent quarters. Revenue surged to $17.0B in 2025, up from $12.9B in 2024, while cash flow from operations improved to $7.7B. A dividend of $0.18 per share is scheduled for payment on June 15, 2026.
The stock presents a value opportunity with a consensus price target of $51.33, implying 39% upside, supported by 68% analyst buy ratings. Risks include gold price volatility and operational execution challenges. Strong cash flow generation and low debt levels provide a solid foundation for growth, though near-term technical weakness may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
